MétaCan
Menu
Back to cohort
Record W2989237601 · doi:10.1016/s0167-8140(19)33260-8

20 Preliminary Results of a Two Stage Phase II Study of 18F-DCFPYL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer

2019· article· en· W2989237601 on OpenAlexaff
Rachel Glicksman, Nafisha Lalani

Bibliographic record

VenueRadiotherapy and Oncology · 2019
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsAblative caseProstate cancerMedicineStage (stratigraphy)Subclinical infectionNuclear medicineProstateOncologyRadiologyCancerRadiation therapyInternal medicineBiology

Abstract

fetched live from OpenAlex

Purpose: Despite maximal local therapies (MLT) (radical prostatectomy followed by radiotherapy [RT]), 20-30% of men will have incurable progression of prostate cancer (PC).Most recurrences in this scenario are characterized by continuous PSA rises and failure of standard imaging (bone scan [BS] and computed tomography [CT]) to detect recurrence sites.We conducted a Phase II trial for men with rising PSA after MLT using 18F-DCFPyL PET-MR/CT followed by targeted ablation of PET positive foci.We report the results of our pre-defined analysis. Materials and Methods:Patients with rising PSA (0.4 -3.0 ng/ mL) after MLT, negative BS/CT and no prior salvage ADT were eligible.All patients underwent 18F-DCFPyL PET-MR followed by immediate PET-CT acquisition.Those with limited disease, where possible, underwent stereotactic ablative RT (SABR) or surgery.No ADT was used.The primary endpoint was biochemical response rate (complete [undetectable PSA] or partial [PSA decline ≥50% compared to baseline]).A Simon's two stage study design was employed.Stage 1 included 12 response-evaluable patients, requiring one or more responses in the absence of Grade 3+ toxicities to proceed to Stage 2 (additional 25 response-evaluable patients).Results: After a median of 58 months (range 29-120) post MLT, 20 patients underwent PET-MR/CT to have 12 response-evaluable patients.Median PSA at enrollment was 1.3 ng/mL (range 0.4-2.8).Three patients had negative PET-MR/CT, while 17 had positive scans, of which 12 (60%) were amenable to response-evaluable ablation.The median number of detected lesions in those treated was 2 (range 1-5).Ten patients underwent SABR (27-30 Gy / 3 fractions) and two had surgery.One patient (8%) had complete and four (33%) had partial PSA responses at a median of 3.3 months (range 2.8-6.0)after ablation, while the remaining seven (59%) did not have biochemical response.No Grade 3+ toxicities were observed.Conclusions: 18F-DCFPyL PET-MR/CT has high detection rates in men with rising PSA after MLT.We observed favorable early results with SABR or surgery (41% RR; no Grade 3+ toxicities).Accrual completion and preliminary results on the entire cohort are expected for Q1 and Q3 2019, respectively.Our study will uniquely inform if ablative approaches offer potential for cure in an early molecularly-defined PC oligometastatic state. 21

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.021

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.068
GPT teacher head0.454
Teacher spread0.385 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractno

Explore more

Same venueRadiotherapy and OncologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207